Glenmark Pharmaceuticals Intrinsic Value

Glenmark Pharmaceuticals intrinsic value. Glenmark Pharmaceuticals (GLENMARK) median intrinsic value is ₹4525.71 from 10 valuation models (range ₹783–₹6521), vs current price ₹2608.50 — +73.5% upside (Trading Below Calculated Value), margin of safety 42.4%. Browse GLENMARK financial statements for revenue, profit, balance sheet and cash flow data.

Market Price (CMP)
₹2608.50
Primary Intrinsic Value
₹822.80
Market Cap
₹7304 Cr
+73.5% Upside
Median Value
₹4525.71
Value Range
₹783 - ₹6521
Assessment
Trading Below Calculated Value
Safety Margin
42.4%

GLENMARK Valuation Methods Summary — DCF, Graham Number & P/E

Glenmark Pharmaceuticals intrinsic value across 10 models vs current price ₹2608.50 — upside/downside and value range per method. Analyse GLENMARK shareholder distribution to track promoter, FII and institutional holdings.

Method Type Intrinsic Value Range Upside/Downside Details
P/E Based Valuation earnings ₹822.80 ₹658.24 - ₹987.36 -68.5% EPS: ₹37.40, Sector P/E: 22x
Book Value Method asset ₹6521.25 ₹5869.12 - ₹7173.38 +150.0% Book Value/Share: ₹3754.29, P/B: 2.0x
Revenue Multiple Method revenue ₹5217.00 ₹4695.30 - ₹5738.70 +100.0% Revenue/Share: ₹5942.86, P/S: 2.0x
EBITDA Multiple Method earnings ₹5217.00 ₹4695.30 - ₹5738.70 +100.0% EBITDA: ₹1968.00Cr, EV/EBITDA: 10x
Simple DCF (5Y) dcf ₹6521.25 ₹5217.00 - ₹7825.50 +150.0% CF Growth: 15.0%, Discount: 15%
PEG Ratio Method growth ₹782.55 ₹704.29 - ₹860.81 -70.0% EPS Growth: 8.0%, Fair P/E: 6.4x
Growth Adjusted P/E growth ₹782.55 ₹704.29 - ₹860.81 -70.0% Revenue Growth: 6.0%, Adj P/E: 15.5x
ROE Based Valuation profitability ₹4525.71 ₹4073.14 - ₹4978.28 +73.5% ROE: 10.0%, P/E Multiple: 12x
Graham Defensive Method conservative ₹1777.42 ₹1599.68 - ₹1955.16 -31.9% EPS: ₹37.40, BVPS: ₹3754.29
Dividend Yield Method dividend ₹782.55 ₹704.29 - ₹860.81 -70.0% DPS: ₹5.00, Target Yield: 2.5%
Method Types: Earnings Asset DCF Growth Dividend Conservative

GLENMARK Intrinsic Value vs Market Price — All Valuation Models

Glenmark Pharmaceuticals fair value range ₹783–₹6521 vs current market price ₹2608.50 across 10 valuation models. For current market price and key ratios, visit Glenmark Pharmaceuticals share price chart.

GLENMARK Intrinsic Value Analysis — Undervalued or Overvalued?

Glenmark Pharmaceuticals median intrinsic value ₹4525.71, current price ₹2608.50 — Trading Below Calculated Value by 73.5%, margin of safety 42.4%.

What is the intrinsic value of GLENMARK?

Based on our comprehensive analysis using 10 different valuation methods, the estimated intrinsic value of Glenmark Pharmaceuticals (GLENMARK) is ₹4525.71 (median value). With the current market price of ₹2608.50, this represents a +73.5% variance from our estimated fair value.

The valuation range spans from ₹782.55 to ₹6521.25, indicating ₹782.55 - ₹6521.25.

Is GLENMARK undervalued or overvalued?

Based on our multi-method analysis, Glenmark Pharmaceuticals (GLENMARK) appears to be trading below calculated value by approximately 73.5%.

GLENMARK Financial Health — Key Ratios vs Industry Benchmarks

Glenmark Pharmaceuticals financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.

Financial Metric Current Value Industry Benchmark Assessment Impact on Valuation
Return on Equity 10.0% Industry Standard: 15%+ Above 10% Measures shareholder return efficiency
Operating Margin 12.0% Industry Standard: 20%+ Above 10% Indicates operational efficiency level
Asset Turnover Ratio 0.84x Industry Standard: 1.0x+ Above 0.5x Measures asset utilization efficiency

GLENMARK Cash Flow Quality — Operating & Free Cash Flow

Glenmark Pharmaceuticals operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.

Period Operating Cash Flow Free Cash Flow Cash Flow Quality Sustainability Score
March 2026 ₹3,445 Cr ₹2,827 Cr Positive Free Cash Flow 8/10
March 2025 ₹-828 Cr ₹-828 Cr Negative Cash Flow 3/10
March 2024 ₹-265 Cr ₹-265 Cr Negative Cash Flow 3/10
March 2023 ₹625 Cr ₹368 Cr Positive Free Cash Flow 8/10
March 2022 ₹1,109 Cr ₹951 Cr Positive Free Cash Flow 8/10